纳入血小板与肝脏硬度比值可提高筛查需治疗食管静脉曲张的准确性
基于10项研究人群2004至2018年数据的回顾性分析,将2368例慢性肝病患者随机分为衍生人群(n=1579)和验证人群(n=789),比较Baveno VI标准、扩展Baveno VI标准、ANTICIPATE评分及新算法VariScreen排除需治疗静脉曲张的表现。VariScreen在衍生人群中节省内镜率34.5%、漏诊需治疗静脉曲张2.9%,是唯一不受性别或病因影响的安全检测。
要点
- 衍生人群中,B6C节省内镜23.9%漏诊2.9%,EB6C节省41.9%漏诊10.9%。
- ANTICIPATE评分节省内镜24.3%漏诊4.6%,VariScreen节省34.5%漏诊2.9%。
- VariScreen是唯一在男女及不同病因中漏诊需治疗静脉曲张均≤5%的检测。
核心结论
- 基于漏诊需治疗静脉曲张,B6C安全而EB6C不安全。
- VariScreen算法在任何病因或严重程度的慢性肝病患者中表现良好,是唯一能安全排除需治疗静脉曲张并可用于临床实践的检测。
研究设计与样本
- 回顾性分析10项研究人群2004年至2018年数据,共2368例不同病因慢性肝病患者。
- 随机分为衍生人群(n=1579;需治疗静脉曲张15.1%,病毒性肝炎50.2%,非酒精性脂肪性肝病28.9%,酒精相关性肝病20.8%,MELD评分9.5±3.0,肝脏硬度测量≥10 kPa者93.0%)和验证人群(n=789)。
- 比较B6C、EB6C、ANTICIPATE评分与序贯算法VariScreen的检测表现。
主要发现
- 衍生人群中,B6C节省内镜23.9%(漏诊需治疗静脉曲张2.9%),ANTICIPATE评分节省24.3%(漏诊4.6%),VariScreen节省34.5%(漏诊2.9%),EB6C节省41.9%(漏诊10.9%)。
- 节省内镜率差异显著(P≤.001),但B6C与ANTICIPATE之间除外;漏诊需治疗静脉曲张仅在EB6C与其他检测比较时差异显著(P≤.009)。
- VariScreen是唯一不受性别或病因影响的安全检测(漏诊需治疗静脉曲张≤5%)。
- VariScreen在MELD评分高于10的患者中实现无漏诊需治疗静脉曲张的筛查。
- 该整体策略优于仅限代偿期肝病患者的selective策略;检测表现和安全性在不同人群间无显著差异。
关键数值与推荐
- B6C:节省内镜23.9%,漏诊需治疗静脉曲张2.9%(衍生人群)。
- ANTICIPATE评分:节省内镜24.3%,漏诊需治疗静脉曲张4.6%(衍生人群)。
- VariScreen:节省内镜34.5%,漏诊需治疗静脉曲张2.9%(衍生人群)。
- EB6C:节省内镜41.9%,漏诊需治疗静脉曲张10.9%(衍生人群)。
- VariScreen安全标准:漏诊需治疗静脉曲张≤5%。
临床怎么用
- 作者结论认为VariScreen是唯一能安全排除需治疗静脉曲张并可用于临床实践的检测。
- 作者结论认为基于漏诊需治疗静脉曲张,B6C安全而EB6C不安全。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Based on platelets and liver stiffness measurements, the Baveno VI criteria (B6C), the expanded B6C (EB6C), and the ANTICIPATE score can be used to rule out varices needing treatment (VNT) in patients with compensated chronic liver disease. We aimed to improve these tests by including data on the ratio of platelets to liver stiffness. METHODS: In a retrospective analysis of data from 10 study populations, collected from 2004 through 2018, we randomly assigned data from 2368 patients with chronic liver disease of different etiologies to a derivation population (n = 1579; 15.1% with VNT, 50.2% with viral hepatitis, 28.9% with nonalcoholic fatty liver disease, 20.8% with alcohol-associated liver disease, with model for end-stage liver disease scores of 9.5 ± 3.0, and 93.0% with liver stiffness measurements ≥10 kPa) or a validation population (n = 789). Test results were compared with results from a sequential algorithm (VariScreen). VariScreen incorporated data on platelets or liver stiffness measurements and then the ratio of platelets to liver stiffness measurement, adjusted for etiology, patient sex, and international normalized ratio. RESULTS: In the derivation population, endoscopies were spared for 23.9% of patients using the B6C (VNT missed in 2.9%), 24.3% of patients using the ANTICIPATE score (VNT missed in 4.6%), 34.5% of patients using VariScreen (VNT missed in 2.9%), and 41.9% of patients using the EB6C (VNT missed in 10.9%). Differences in spared endoscopy rates were significant (P ≤ .001), except for B6C vs ANTICIPATE and in missed VNT only for EB6C vs the others (P ≤ .009). VariScreen was the only safe test regardless of sex or etiology (missed VNT ≤5%). Moreover, VariScreen secured screening without missed VNT in patients with model for end-stage liver disease scores higher than 10. This overall strategy performed better than a selective strategy restricted to patients with compensated liver disease. Test performance and safety did not differ significantly among populations. CONCLUSIONS: In a retrospective study of data from 2368 patients with chronic liver disease, we found that the B6C are safe whereas the EB6C are unsafe, based on missed VNT. The VariScreen algorithm performed well in patients with chronic liver disease of any etiology or severity. It is the only test that safely rules out VNT and can be used in clinical practice.
引用
- Berger A, Ravaioli F, Farcau O, et al. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. Clin Gastroenterol Hepatol. 2020. PMID: 32562889. doi:10.1016/j.cgh.2020.06.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。